Your browser doesn't support javascript.
loading
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Berglund, Åke; Ullén, Anders; Lisyanskaya, Alla; Orlov, Sergey; Hagberg, Hans; Tholander, Bengt; Lewensohn, Rolf; Nygren, Peter; Spira, Jack; Harmenberg, Johan; Jerling, Markus; Alvfors, Carina; Ringbom, Magnus; Nordström, Eva; Söderlind, Karin; Gullbo, Joachim.
Affiliation
  • Berglund Å; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Ullén A; Department of Oncology, Karolinska University Hospital, Solna, Sweden.
  • Lisyanskaya A; St. Petersburg State Healthcare Institution, City Clinical Oncology Center, Saint Petersburg, Russia.
  • Orlov S; State Educational Institution of Higher Professional Education, St. Petersburg State Medical University, n.a. I.P. Pavlov of Roszdrav, Saint Petersburg, Russia.
  • Hagberg H; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Tholander B; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Lewensohn R; Department of Oncology, Karolinska University Hospital, Solna, Sweden.
  • Nygren P; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Spira J; Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm, Sweden.
  • Harmenberg J; Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm, Sweden.
  • Jerling M; Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm, Sweden.
  • Alvfors C; Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden.
  • Ringbom M; Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden.
  • Nordström E; Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm, Sweden.
  • Söderlind K; Oncopeptides AB, Västra Trädgårdsgatan 15, Stockholm, Sweden.
  • Gullbo J; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. joachim.gullbo@medsci.uu.se.
Invest New Drugs ; 33(6): 1232-41, 2015 Dec.
Article in En | MEDLINE | ID: mdl-26553306
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylalanine / Antineoplastic Agents, Alkylating / Melphalan / Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2015 Type: Article Affiliation country: Sweden
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylalanine / Antineoplastic Agents, Alkylating / Melphalan / Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2015 Type: Article Affiliation country: Sweden